{"id":6422,"date":"2015-11-05T19:57:00","date_gmt":"2015-11-05T18:57:00","guid":{"rendered":"https:\/\/www.osatzen.com\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/"},"modified":"2021-06-07T13:16:32","modified_gmt":"2021-06-07T11:16:32","slug":"alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica","status":"publish","type":"post","link":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/","title":{"rendered":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?"},"content":{"rendered":"<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<h2 style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;verdana&quot; , sans-serif; font-size: 18.666666666666664px; font-style: normal; font-variant: normal; font-weight: 700; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">Ez dirudi alopurinolak nefropatia diabetikoa prebenitzen duenik giltzurruneko gaixotasun kronikorik gabeko hiperurizemia asintomatikoa duten 2 motako diabetikoetan<\/span><\/span><\/span><\/h2>\n<\/div>\n<table cellpadding=\"0\" cellspacing=\"0\" style=\"float: right; margin-left: 1em; text-align: right;\">\n<tbody>\n<tr>\n<td style=\"text-align: center;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><a href=\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\" style=\"clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;\"><img decoding=\"async\" border=\"0\" src=\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\" \/><\/a><\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\">La imagen es de<a href=\"http:\/\/footage.framepool.com\/es\/search\/sistema%2Brenale\/\"> aqu\u00ed<\/a><\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"text-align: left;\"><span style=\"font-size: small;\"><span style=\"font-family: &quot;arial&quot; , &quot;helvetica&quot; , sans-serif;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Jarraian datorren galdeari erantzuteko hautatutako <\/span><a href=\"http:\/\/es.slideshare.net\/mbeosatzen\/lectura-crtica-alopurinol-en-diabticos-tipo-2-con-hiperuricemia-asintomtica\" style=\"text-decoration: none;\" target=\"_blank\" rel=\"noopener\"><span style=\"background-color: transparent; color: #1155cc; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">artikuluaren irakurketa kritikoa<\/span><\/a><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"> burutu ostean:<\/span><\/span><\/span><\/span><\/span><\/div>\n<p><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><br \/><\/span><\/span><\/p>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: left;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 700; vertical-align: baseline; white-space: pre-wrap;\">Alopurinolak nefropatia diabetikoa prebenitzen du hiperuricemia asintomatikoa duten 2 motako diabetikoetan? PICO:<\/span><\/span><\/span><br \/><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 700; vertical-align: baseline; white-space: pre-wrap;\"><\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<ul>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">P (Paciente) = Gaixoa: Hiperurizemia asintomatikoa duen 2 motako diabetikoa.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">I (Intervenci\u00f3n) = Interbentzioa: Alopurinolarekin tratamendua.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">C (Comparaci\u00f3n) = Konparazioa: Ohiko tratamenduak.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">O (Outcome) = Emaitza: Giltzurrun gutxiegitasunaren aurreratzea murriztea, erikortasun eta hilkortasun kardiobaskularra, eragin desiragaitzak.<\/span><\/span><\/span><\/li>\n<\/ul>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<h3><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 700; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">Gure ondorioa hauxe da:<\/span><\/span><\/span><\/h3>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Azterketa nefropatia gabeko diabetiko txinatarretan egina dago, eta beraz, hainbat ezaugarri ez datoz bat gure komunitatearekin (antidiabetiko orala eta intsulinarekin tratatutako gaixo portzentaia txikiagoa, gaixo zaharragoak eta gizenagoak). Ondorioz, azterketaren kanpo-baliotasuna eztabaidagarria da.<\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Alopurinolak albumina iraizketa nabarmenki gutxitzen badu ere, barne-baliotasunari dagokionean, ikerketak muga garrantzitsuak ditu: gaixo kopuru txikia, itsutasun eza, plazeboarekin tratatutako kontrol taldearen falta eta analisian mugak (AIT-aren ordez APP) aldagai gehientsuenetan. Beraz, esan genezake, emaitzetan dugun konfiantza oso baxua dela.<\/span><\/span><\/span><\/div>\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><br \/><\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Emaitzak CAT formatuan aurkeztu ditugu, eta<\/span><a href=\"http:\/\/es.slideshare.net\/mbeosatzen\/cat-alopurinol-y-diabticos\" style=\"text-decoration: none;\" target=\"_blank\" rel=\"noopener\"><span style=\"background-color: transparent; color: #1155cc; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\"> lotura honen<\/span><\/a><span style=\"background-color: transparent; color: #0070c0; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"> <\/span><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">bidez sar zaitezke bertara.<\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Era berean, azterketa honetaz baliatuz, diseinu paralelodun ASK* (ECA)-<\/span><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ren<\/span><span style=\"background-color: transparent; color: #1155cc; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\"> <\/span><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">errepaso teorikoa egin dugu.<\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: italic; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">*Ausazko saiakuntza klinikoa = Ensayo cl\u00ednico aleatorizado<\/span><\/span><\/span><\/div>\n<p><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><br \/><\/span><\/span><\/p>\n<h2 style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;verdana&quot; , sans-serif; font-size: 18.6667px; font-weight: 700; line-height: 1.38; text-decoration: underline; white-space: pre-wrap;\">El tratamiento con alopurinol en <span style=\"font-family: &quot;verdana&quot; , sans-serif;\">d<\/span>iab\u00e9ticos tipo 2 &nbsp;sin enfermedad renal cr\u00f3nica y con &nbsp;hiperuricemia asintom\u00e1tica no parece prevenir la nefropat\u00eda diab\u00e9tica<\/span><\/span><\/span><\/h2>\n<p><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; vertical-align: baseline; white-space: pre-wrap;\">Tras realizar la <\/span><a href=\"http:\/\/es.slideshare.net\/mbeosatzen\/lectura-crtica-alopurinol-en-diabticos-tipo-2-con-hiperuricemia-asintomtica\" style=\"line-height: 1.38; text-decoration: none;\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #1155cc; font-family: &quot;arial&quot;; font-size: 16px; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">lectura cr\u00edtica del art\u00edculo seleccionado<\/span><\/a><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; vertical-align: baseline; white-space: pre-wrap;\">, para responder a la pregunta:<\/span><\/span><\/span><br \/><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; font-weight: 700; line-height: 1.38; white-space: pre-wrap;\"><br \/><\/span><\/span><\/span><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; font-weight: 700; line-height: 1.38; white-space: pre-wrap;\">\u00bfEl tratamiento con alopurinol en pacientes diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica previene la nefropat\u00eda diab\u00e9tica? PICO:<\/span><\/span><\/span><\/p>\n<div dir=\"ltr\" style=\"line-height: 1.3800000000000001; margin-bottom: 0pt; margin-top: 0pt;\"><span style=\"font-family: inherit;\"><\/span><\/p>\n<ul>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">Paciente: Diab\u00e9tico tipo 2 con hiperuricemia asintom\u00e1tica.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">Intervenci\u00f3n: Tratamiento con alopurinol.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">Comparaci\u00f3n: Tratamientos convencionales.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"font-family: &quot;arial&quot;; font-size: 16px; line-height: 1.38; white-space: pre-wrap;\">Outcome: Disminuci\u00f3n progresi\u00f3n IR, morbimortalidad CV, efectos adversos. <\/span><\/span><\/span><\/li>\n<\/ul>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-right: -29.25pt; margin-top: 0pt;\">\n<h3><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 700; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">Nuestra conclusi\u00f3n es la siguiente:<\/span><\/span><\/span><\/h3>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">El estudio est\u00e1 realizado en pacientes chinos diab\u00e9ticos sin nefropat\u00eda que difieren en algunas caracter\u00edsticas de los pacientes de nuestra comunidad (menor porcentaje de pacientes en tratamiento con antidiab\u00e9ticos orales m\u00e1s insulina, pacientes mayores y m\u00e1s obesos), por lo que la validez externa del estudio est\u00e1 cuestionada.<\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: justify;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Aunque el alopurinol disminuye significativamente la excreci\u00f3n de alb\u00famina, respecto a la validez interna, el estudio presenta importantes limitaciones metodol\u00f3gicas: la inclusi\u00f3n de pocos pacientes, ausencia de ciego, falta de grupo control con placebo as\u00ed como limitaciones en el an\u00e1lisis (APP en lugar de AIT) en la mayor\u00eda de las variables por lo que la confianza en los resultados es muy baja.<\/span><\/span><\/span><br \/><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><br \/><\/span><\/span><\/span><\/div>\n<\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Presentamos los resultados en formato CAT al que puedes acceder <\/span><a href=\"http:\/\/es.slideshare.net\/mbeosatzen\/cat-alopurinol-y-diabticos\" style=\"text-decoration: none;\" target=\"_blank\" rel=\"noopener\"><span style=\"background-color: transparent; color: #1155cc; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;\">aqu\u00ed.<\/span><\/a><\/span><\/span><\/div>\n<div dir=\"ltr\" style=\"line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;\">\n<div style=\"text-align: left;\"><span style=\"font-family: inherit;\"><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Y aprovechamos para hacer un repaso te\u00f3rico del ECA con dise\u00f1o paralelo<\/span><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">.<\/span><\/span><\/span><\/div>\n<p><span style=\"font-family: inherit;\"><span style=\"background-color: transparent; color: black; font-family: &quot;arial&quot;; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><br \/><\/span><\/span><\/div>\n<div style=\"text-align: center;\"><span style=\"font-family: inherit;\"><iframe allowfullscreen=\"\" frameborder=\"0\" height=\"355\" marginheight=\"0\" marginwidth=\"0\" scrolling=\"no\" src=\"\/\/es.slideshare.net\/slideshow\/embed_code\/key\/2WhaGAH7GMxNtE\" style=\"border-width: 1px; border: 1px solid #CCC; margin-bottom: 5px; max-width: 100%;\" width=\"425\"> <\/iframe><\/span> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ez dirudi alopurinolak nefropatia diabetikoa prebenitzen duenik giltzurruneko gaixotasun kronikorik gabeko hiperurizemia asintomatikoa duten 2 motako diabetikoetan La imagen es de aqu\u00ed Jarraian datorren galdeari erantzuteko hautatutako artikuluaren irakurketa kritikoa burutu ostean: Alopurinolak nefropatia diabetikoa  [&#8230;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[616,624,580,597,581,615,614,592],"tags":[],"class_list":["post-6422","post","type-post","status-publish","format-standard","hentry","category-alopurinol","category-blog-salabardo-mbe","category-cat","category-diabeticos-tipo-2","category-lectura-critica","category-nefropatia-diabetica","category-presentacion","category-tratamiento"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3 (Yoast SEO v25.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica? - Osatzen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\" \/>\n<meta property=\"og:locale\" content=\"eu_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?\" \/>\n<meta property=\"og:description\" content=\"Ez dirudi alopurinolak nefropatia diabetikoa prebenitzen duenik giltzurruneko gaixotasun kronikorik gabeko hiperurizemia asintomatikoa duten 2 motako diabetikoetan La imagen es de aqu\u00ed Jarraian datorren galdeari erantzuteko hautatutako artikuluaren irakurketa kritikoa burutu ostean: Alopurinolak nefropatia diabetikoa [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\" \/>\n<meta property=\"og:site_name\" content=\"Osatzen\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Osatzen\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-05T18:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-06-07T11:16:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\" \/>\n<meta name=\"author\" content=\"BLOG EL SALABARDO - MBE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@osatzen\" \/>\n<meta name=\"twitter:site\" content=\"@osatzen\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BLOG EL SALABARDO - MBE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\"},\"author\":{\"name\":\"BLOG EL SALABARDO - MBE\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/59f76d6c5831dff8ca4050643ea3aedb\"},\"headline\":\"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?\",\"datePublished\":\"2015-11-05T18:57:00+00:00\",\"dateModified\":\"2021-06-07T11:16:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\",\"articleSection\":[\"alopurinol\",\"BLOG SALABARDO MBE\",\"CAT\",\"diab\u00e9ticos tipo 2\",\"lectura cr\u00edtica\",\"nefropat\u00eda diab\u00e9tica\",\"presentaci\u00f3n\",\"tratamiento\"],\"inLanguage\":\"eu-ES\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\",\"url\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\",\"name\":\"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica? - Osatzen\",\"isPartOf\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\",\"datePublished\":\"2015-11-05T18:57:00+00:00\",\"dateModified\":\"2021-06-07T11:16:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#breadcrumb\"},\"inLanguage\":\"eu-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"eu-ES\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage\",\"url\":\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\",\"contentUrl\":\"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.osatzen.com\/eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#website\",\"url\":\"https:\/\/www.osatzen.com\/eu\/\",\"name\":\"Osatzen\",\"description\":\"Sociedad Vasca de Medicina de Familia y Comunitaria\",\"publisher\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.osatzen.com\/eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"eu-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#organization\",\"name\":\"Osatzen\",\"url\":\"https:\/\/www.osatzen.com\/eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"eu-ES\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.osatzen.com\/wp-content\/uploads\/2021\/02\/signo-distintivo-osatzen-2020-web-retina-396x120-1.png\",\"contentUrl\":\"https:\/\/www.osatzen.com\/wp-content\/uploads\/2021\/02\/signo-distintivo-osatzen-2020-web-retina-396x120-1.png\",\"width\":396,\"height\":120,\"caption\":\"Osatzen\"},\"image\":{\"@id\":\"https:\/\/www.osatzen.com\/eu\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Osatzen\",\"https:\/\/x.com\/osatzen\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/59f76d6c5831dff8ca4050643ea3aedb\",\"name\":\"BLOG EL SALABARDO - MBE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"eu-ES\",\"@id\":\"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2af25a14e5da1c9bfb0a6c9ac7cbdce7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2af25a14e5da1c9bfb0a6c9ac7cbdce7?s=96&d=mm&r=g\",\"caption\":\"BLOG EL SALABARDO - MBE\"},\"description\":\"La idea de este blog es favorecer la ense\u00f1anza y pr\u00e1ctica de la medicina basada en la evidencia (MBE) . En \u00e9l podr\u00e1n encontrarse materiales elaborados por el grupo MBE Osatzen en forma de respuestas a dudas cl\u00ednicas y metodol\u00f3gicas, evaluaciones de art\u00edculos originales, etc, Pero el blog podr\u00e1 recoger cualquier otra iniciativa de inter\u00e9s relacionada con la mejora de la pr\u00e1ctica cl\u00ednica en atenci\u00f3n primaria.\",\"url\":\"https:\/\/www.osatzen.com\/eu\/blogs\/author\/blogelsalabardo\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica? - Osatzen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/","og_locale":"eu_ES","og_type":"article","og_title":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?","og_description":"Ez dirudi alopurinolak nefropatia diabetikoa prebenitzen duenik giltzurruneko gaixotasun kronikorik gabeko hiperurizemia asintomatikoa duten 2 motako diabetikoetan La imagen es de aqu\u00ed Jarraian datorren galdeari erantzuteko hautatutako artikuluaren irakurketa kritikoa burutu ostean: Alopurinolak nefropatia diabetikoa [...]","og_url":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/","og_site_name":"Osatzen","article_publisher":"https:\/\/www.facebook.com\/Osatzen","article_published_time":"2015-11-05T18:57:00+00:00","article_modified_time":"2021-06-07T11:16:32+00:00","og_image":[{"url":"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg","type":"","width":"","height":""}],"author":"BLOG EL SALABARDO - MBE","twitter_card":"summary_large_image","twitter_creator":"@osatzen","twitter_site":"@osatzen","twitter_misc":{"Written by":"BLOG EL SALABARDO - MBE","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#article","isPartOf":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/"},"author":{"name":"BLOG EL SALABARDO - MBE","@id":"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/59f76d6c5831dff8ca4050643ea3aedb"},"headline":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?","datePublished":"2015-11-05T18:57:00+00:00","dateModified":"2021-06-07T11:16:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/www.osatzen.com\/eu\/#organization"},"image":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage"},"thumbnailUrl":"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg","articleSection":["alopurinol","BLOG SALABARDO MBE","CAT","diab\u00e9ticos tipo 2","lectura cr\u00edtica","nefropat\u00eda diab\u00e9tica","presentaci\u00f3n","tratamiento"],"inLanguage":"eu-ES","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/","url":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/","name":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica? - Osatzen","isPartOf":{"@id":"https:\/\/www.osatzen.com\/eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage"},"image":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage"},"thumbnailUrl":"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg","datePublished":"2015-11-05T18:57:00+00:00","dateModified":"2021-06-07T11:16:32+00:00","breadcrumb":{"@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#breadcrumb"},"inLanguage":"eu-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/"]}]},{"@type":"ImageObject","inLanguage":"eu-ES","@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#primaryimage","url":"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg","contentUrl":"https:\/\/osatzen.com\/wp-content\/uploads\/2021\/06\/nefrona4.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.osatzen.com\/eu\/blogs\/alopurinol-en-diabeticos-tipo-2-con-hiperuricemia-asintomatica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.osatzen.com\/eu\/"},{"@type":"ListItem","position":2,"name":"\u00bfAlopurinol en diab\u00e9ticos tipo 2 con hiperuricemia asintom\u00e1tica?"}]},{"@type":"WebSite","@id":"https:\/\/www.osatzen.com\/eu\/#website","url":"https:\/\/www.osatzen.com\/eu\/","name":"Osatzen","description":"Sociedad Vasca de Medicina de Familia y Comunitaria","publisher":{"@id":"https:\/\/www.osatzen.com\/eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.osatzen.com\/eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"eu-ES"},{"@type":"Organization","@id":"https:\/\/www.osatzen.com\/eu\/#organization","name":"Osatzen","url":"https:\/\/www.osatzen.com\/eu\/","logo":{"@type":"ImageObject","inLanguage":"eu-ES","@id":"https:\/\/www.osatzen.com\/eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.osatzen.com\/wp-content\/uploads\/2021\/02\/signo-distintivo-osatzen-2020-web-retina-396x120-1.png","contentUrl":"https:\/\/www.osatzen.com\/wp-content\/uploads\/2021\/02\/signo-distintivo-osatzen-2020-web-retina-396x120-1.png","width":396,"height":120,"caption":"Osatzen"},"image":{"@id":"https:\/\/www.osatzen.com\/eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Osatzen","https:\/\/x.com\/osatzen"]},{"@type":"Person","@id":"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/59f76d6c5831dff8ca4050643ea3aedb","name":"BLOG EL SALABARDO - MBE","image":{"@type":"ImageObject","inLanguage":"eu-ES","@id":"https:\/\/www.osatzen.com\/eu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2af25a14e5da1c9bfb0a6c9ac7cbdce7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2af25a14e5da1c9bfb0a6c9ac7cbdce7?s=96&d=mm&r=g","caption":"BLOG EL SALABARDO - MBE"},"description":"La idea de este blog es favorecer la ense\u00f1anza y pr\u00e1ctica de la medicina basada en la evidencia (MBE) . En \u00e9l podr\u00e1n encontrarse materiales elaborados por el grupo MBE Osatzen en forma de respuestas a dudas cl\u00ednicas y metodol\u00f3gicas, evaluaciones de art\u00edculos originales, etc, Pero el blog podr\u00e1 recoger cualquier otra iniciativa de inter\u00e9s relacionada con la mejora de la pr\u00e1ctica cl\u00ednica en atenci\u00f3n primaria.","url":"https:\/\/www.osatzen.com\/eu\/blogs\/author\/blogelsalabardo\/"}]}},"_links":{"self":[{"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/posts\/6422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/comments?post=6422"}],"version-history":[{"count":1,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/posts\/6422\/revisions"}],"predecessor-version":[{"id":6511,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/posts\/6422\/revisions\/6511"}],"wp:attachment":[{"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/media?parent=6422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/categories?post=6422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.osatzen.com\/eu\/wp-json\/wp\/v2\/tags?post=6422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}